MaxCyte, Inc., (NASDAQ: MXCT) saw its shares dip slightly Wednesday. The cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, marks the 25th anniversary of its founding this year. Over the past quarter-century, the company has remained steadfast in its mission to provide the life sciences community with the necessary technologies, as well as scientific, technical and regulatory support, to develop biomedical innovations that will transform human health.
“Since the Company’s inception, MaxCyte set out to commercialize Flow Electroporation® technology with a talented global team and, over the years, we have developed and launched a suite of products within our proprietary ExPERT™ platform,” said Maher Masoud, President and CEO of MaxCyte. “Today, we are proud to provide our customers with best-in-class electroporation solutions and tools. Knowing that our customers and their patients come first drives us to find the solutions to meet their needs as we enter the next era of scientific discovery and development focused on cell and gene therapy.”
To quote this morning’s news release, “to continue supporting its customers in their journey through therapeutic development to commercialization, in 2022 MaxCyte moved to its present headquarters, a 67,000 square-foot facility located in Maryland’s I-270 biotech corridor, which significantly increased the Company’s in-house manufacturing capacity, as well as research and process development lab space.”
MXCT shares handed over 2.5 cents to $3.51.
Related Stories
